ABCL — AbCellera Biologics Income Statement
0.000.00%
- $870.40m
- $172.38m
- $38.03m
- 52
- 27
- 32
- 30
Annual income statement for AbCellera Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 11.6 | 233 | 375 | 485 | 38 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 15.7 | 80.8 | 171 | 269 | 275 |
Operating Profit | -4.12 | 152 | 204 | 217 | -237 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.21 | 158 | 219 | 239 | -174 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.21 | 119 | 153 | 159 | -146 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.21 | 119 | 153 | 159 | -146 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.21 | 119 | 153 | 159 | -146 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.008 | 0.452 | 0.482 | 0.504 | -0.499 |
Dividends per Share |